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APC: More than a beta (catenin) blocker
T
he adenomatous polyposis coli 
(APC) protein serves as the co-
lon’s guardian, keeping tumors at 
bay. Okada et al. (1) reveal a new function 
for the protein: helping to renovate the 
cytoskeleton by triggering actin assembly. 
The result suggests a second way that muta-
tions in APC could lead to cancer.
A faulty APC gene occurs in more than 
80% of colon cancers and is one of the 
early “gateway” mutations leading to ab-
normal growth. Researchers probing APC’s 
anti-cancer powers have focused on how it 
curbs the activity of -catenin, a key link in 
the Wnt pathway that manages cell divi-
sion and differentiation (2). But APC also 
helps shape the cytoskeleton. The protein 
latches onto and stabilizes growing micro-
tubule ends (3, 4) and connects to actin fi  la-
ments (5). “There have been more and 
more clues in the literature that the loss of 
APC’s cytoskeletal effects may contribute 
to cancer,” says senior author Bruce Goode. 
Still unknown, however, was how APC 
alters the actin cytoskeleton.
To fi nd out, Okada et al. experimented 
with a C-terminal fragment of APC that 
interacts with microtubules and actin. This 
pruned protein triggered actin polymer-
ization in vivo and in vitro, 
the team showed.
The researchers then 
compared APC’s methods 
to those of other actin nu-
cleators that spur fi  laments 
to grow. The Arp2/3 com-
plex, for instance, almost 
tricks actin into polymer-
izing because it resembles 
the fast-growing barbed 
end of a fi  lament. By con-
trast, researchers think that 
formins such as mDia1 
take a more passive approach, stepping in 
to stabilize short actin chains that form 
spontaneously. A third category, which 
includes Spire and Cobl, plays matchmaker, 
gathering actin monomers that unite into 
a polymer seed. Okada et al. found that 
APC dimerizes and then works like the 
Spire-containing group, corralling up to 
four actin monomers into a complex that 
seeds further elongation.
But that discovery raised another ques-
tion. Cells deploy proteins that rein in 
actin extension. For example, profi  lin 
latches onto actin monomers and curbs 
spontaneous nucleation. And capping 
protein seals the barbed ends of actin fi  la-
ments, preventing them from elongating 
and thus limiting their growth. APC can 
assemble actin fi  laments even if profi  lin is 
around. But how does it 
overcome capping protein?
The answer is that APC 
gets help, collaborating with 
formins that deter capping 
protein. Okada et al. found 
that when capping protein 
and profi  lin are present, APC 
or mDia1 alone is a weak 
nucleator. But combining the 
two boosts actin assembly 
nearly fourfold.
APC is the seventh actin 
nucleator that researchers 
have identifi  ed. “The cellular functions of 
actin are so pervasive,” Goode says. “It’s 
involved in dozens of critical processes, so 
it makes sense that cells have a large num-
ber of factors that promote actin assembly.” 
So far, APC is the only nucleator with 
direct links to cancer. Goode says that it’s 
plausible that APC mutations could foment 
tumors not just through their effects on 
Wnt signaling, but also through their 
impact on the cytoskeleton. Cancer-causing 
mutations typically lop off the protein’s 
actin-binding section.
Colon epithelial cells are born deep in 
crypts in the intestinal lining, and as they 
mature they differentiate, migrate into posi-
tion, and give up their ability to divide. 
These choreographed changes involve 
precise rearrangements of the cytoskeleton 
and, if disrupted, could lead a cell down the 
path to cancer. By creating mice with a ver-
sion of APC that can’t nucleate actin, the 
researchers hope to nail down whether this 
mechanism contributes to tumor formation.
Because APC directly lengthens micro-
tubules and actin, the protein could serve 
as an intermediary between the two cyto-
skeletons. So another question to investi-
gate, the researchers say, is APC’s role in 
situations where microtubules and actin 
remodel in concert, such as cell protru-
sion and migration.
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A team led by Bruce Goode (left) and Kyoko Okada (shown here with lab dog Sasha) discovered 
that the tumor suppressor APC can trigger actin polymerization. This image of a layer of cells 
highlights the actin structures that formed in one cell after an injection of an APC fragment. The 
inset reveals that the GFP-tagged fragment latched onto actin.
“The cellular 
functions of 
actin are so 
pervasive… 
cells have a 
large number 
of factors that 
promote actin 
assembly.”
Tumor suppressor could stop cancer through its effect on actin cytoskeleton.
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